CytRx Corporation (Nasdaq: CYTR) has initiated an open-label, single-center Phase 1b clinical trial to evaluate the pharmacokinetics of its tumor-targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE